Dermatology

Skin cancer checks, eczema/psoriasis, acne care, and cosmetic dermatology news.

  • 4 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Dermatology


newbeauty.com > view > rhapsido-approved-for-symptomatic-dermographism

A Daily Pill for Chronic Hives Just Got a Major Expansion

10+ hour, 40+ min ago   (404+ words) For people whose hives flare from everyday pressure and friction, antihistamines are no longer the only answer. If light pressure, a scratch or even the strap of your bag leaves raised, itchy welts on your skin, there’s new relief on…...


news-medical.net-medical.net

Rare dendritic cells may promote immune tolerance in metastatic cancer

2+ hour, 49+ min ago   (407+ words) Q: What challenges or unmet needs make this study important? For many patients, our main option to treat ascites is to repeatedly drain liters of this fluid to relieve their symptoms and then discard that material. We saw an opportunity to…...


cairnslocalnews.com.au > city-in-skin-cancer-limelight-2026-10-09

City in skin cancer limelight

6+ hour, 29+ min ago   (319+ words) The inaugural Australasian Dermoscopy Meeting 2026 until tomorrow, involves delegates travelling from Australia, New Zealand, Europe, South America and the United States. The venue and three-day conference dates was conceived in Cairns by local doctor Dr Vin Rajeswaran, who approached Tourism…...


ucb.com > newsroom > press-releases > article > bimzelxrbimekizumab-demonstrates-superior-efficacy-over-skyrizir-risankizumab-in-psoriatic-arthritis-be-bold-week-16-data

BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD Week 16 data | UCB

7+ hour, 4+ min ago   (494+ words) Brussels (Belgium), May 19, 2026 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced Week 16 data from the BE BOLD trial demonstrating superior ACR50 joint outcomes at Week 16 for BIMZELX®(bimekizumab) versus SKYRIZI®(risankizumab) in adults living with active psoriatic arthritis (PsA). The results…...


managedhealthcareexecutive.com > conferences > 2026-fall-clinical-dermatology-conference

2026 Fall Clinical Dermatology Conference | Conferences | Managed Healthcare Executive

3+ hour, 30+ min ago   (122+ words) gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions. 2026 Fall Clinical Dermatology Conference 8 dermatology developments from 2026 that experts say matter most | 2026 Fall Clinical Derm Breakthroughs in 2026 dermatology spotlight oral psoriasis drugs nearing biologics, weight-loss…...


managedhealthcareexecutive.com > view > 8-dermatology-developments-from-2026-that-experts-say-matter-most-2026-fall-clinical-derm

8 dermatology developments from 2026 that experts say matter most | 2026 Fall Clinical Derm

3+ hour, 31+ min ago   (781+ words) Breakthroughs in 2026 dermatology spotlight oral psoriasis drugs nearing biologics, weight-loss combos for PsA, personalized mRNA melanoma vaccines and expanding OTC acne options. Pills that rival biologics, weight-loss drugs paired with psoriasis treatment and a phase 3 win for a personalized mRNA…...


news.bloomberglaw.com > securities-law > moderna-sheds-investor-lawsuit-over-rsv-vaccine-efficacy-figure

Moderna Sheds Investor Lawsuit Over RSV Vaccine Efficacy Figure

11+ hour, 45+ min ago   (48+ words) Bloomberg Law News Moderna Inc. and three top executives batted away investor allegations of overstating the efficacy level of its vaccine candidate for respiratory syncytial virus in 2024. Learn more about Bloomberg Law or Log In to keep reading:...


foxnews.com > video > 6406495118112

'Big step forward': Nolla Health to diagnose acne and send prescriptions

10+ hour, 21+ min ago   (40+ words) Fox News 'Big step forward': Nolla Health to diagnose acne and send prescriptions Nolla Health CEO Luis Wenus has the latest on the AI prescription service on 'America Reports.'...


pluang.com > en > news-feed > kolaborasi-northwest-biotherapeutics-dan-nhs-untuk-produksi-dcvax-l

Northwest Biotherapeutics partners with UK NHS to produce experimental cancer vaccine DCVax-L

10+ hour, 31+ min ago   (256+ words) Northwest Biotherapeutics has partnered with the UK National Health Service Blood and Transplant (NHSBT) to support production of its experimental cancer vaccine DCVax-L, targeting glioblastoma and other solid tumors. NHSBT's therapeutic apheresis and cell processing teams in Leeds and Oxford…...